arrow_back Back Filing freshness 10-K Q4 FY2025 SEC EDGAR

Roivant Sciences Ltd.

ROIV
$36.33 ▲ +1.22 (+3.47%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
24 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
52
Health
Fair
Neutral
auto_awesome

Analytical Summary

Roivant Sciences Ltd. shows mixed fundamentals. Consider comparing against peers in the Healthcare sector before making investment decisions.

Market Cap
Dividend Yield
Revenue Growth -66.7%
Op. Margin None
ROIC 7.2%
FCF / Share None
Trailing P/E 80.7x
Price / Book 5.8x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

24-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$2.52M
↓ -66.7%
Net Income Profit after all expenses
$302.99M
↑ +214.0%
FCF / Share Free cash flow per share
$-0.29
↓ -1.7%
Long-Term Debt Long-term obligations
$311.72M
↓ -22.7%

Health Breakdown

Returns
37
Cash Quality
90

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 6 years · 24 quarters